Amendments to Bylaws, Management Change/Compensation (Form 8-K)

On September 23, 2025, FOXO Technologies Inc., a Delaware corporation (the "Company"), appointed Sylwia Nowak Hauman (age 50) as the Company's Chief Financial Officer (Principal Financial and Accounting Officer).

Ms. Hauman has more than 25 years of finance and administrative leadership expertise in public and private multi-billion and start-up companies including extensive pharmaceutical and biotech experience from several multinational companies including Pearsanta, Aditxt (VP, Corporate Controller from May 2022 to September 2024), Lonza, Air Liquide Advanced Materials (Controller from September 2018 to August 2020), Johnson & Johnson, Accord Healthcare (Finance Director - Sales & Gross to Net from January 2020 to April 2022), and Alvogen as well as FDA regulated companies such as, Unilever and Avon. She has served as VP of Finance at Payall Payment Systems, Inc. from September 2024 to the present. She has run and managed several international projects and helped design the Innovation Process Management method to successfully develop and commercialize new technologies. Ms. Hauman is a Certified Accountant, holds a Master's degree in finance and Banking from Lodz University and is qualified in both US GAAP and IFRS.

There are no family relationships between Ms. Hauman and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer.

Pursuant to her appointment as Chief Financial Officer, the board of directors approved Ms. Hauman being paid an annual salary of $200,000 with a possible bonus of $25,000.

On September 22, 2025, the Company filed an amendment to the Company's Certificate of Incorporation (the "Certificate of Incorporation"), in the form of an Amended and Restated Certificate of Designation (the "Amended Designation") of the Company's previously designated "Series A Cumulative Convertible Redeemable Preferred Stock" (the "Series A Preferred Stock"). The Amended Designation: increases the authorized shares of Series A Preferred stock to 50,000, revises the voting rights to entitle the holder of Series A Preferred Stock to cast the number of votes determined by dividing the Stated Value of such share of Series A Preferred Stock by $0.0001 (such dollar amount not being subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Class A Common Stock), revises the conversion price to equal the higher of $0.0001 (such dollar amount not being subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Class A Common Stock) or 90% of the average VWAP of the five trading days immediately prior to the date the Conversion Notice is tendered by the holder, and allows cash dividends to be paid to holders of the Company's Series E Cumulative Redeemable Secured Preferred Stock.

The summary of the rights, privileges and preferences of the Series A Preferred Stock described above is qualified in its entirety by reference to the Amended Designation, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and are incorporated herein by reference.